Clinical Trials Sponsored by CuraGen Corporation

Total 6537 results

CuraGen Corporation

Completed

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Stomatitis | Oral Mucositis

United States
CuraGen Corporation

Completed

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
CuraGen Corporation

Completed

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

Stomatitis

United States
CuraGen Corporation

Completed

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
Covagen

Terminated

Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Germany
CuraSen Therapeutics, Inc.

Not yet recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Freezing of Gait Symptoms in Parkinson's Disease

Australia
CuraSen Therapeutics, Inc.

Completed

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Dementia | Mild Cognitive Impairment

United States, New Zealand
AuraGen Aesthetics LLC

Terminated

Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Autologous Fat Grafting

United States
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
Aceragen

Withdrawn

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations (REPRIEVE)

Cystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation

United States
Sumagen

Completed

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

HIV Infections

United States
Ceragem Clinical Inc.

Recruiting

CETIS-I (CEra Traction Improves Spine-I)

Lumbar Disc Herniation | Degenerative Spinal Stenosis | Spine Traction

Korea, Republic of
Ceragem Clinical Inc.

Recruiting

CEFID-II (CEra Flow Improves DVT-II)

Deep Vein Thrombosis | Blood Circulation Disorder

Korea, Republic of
Ceragem Clinical Inc.

Completed

CEFID-I (CEra Flow Improves DVT-1)

Deep Vein Thrombosis | Blood Circulation Disorder

Korea, Republic of
Ceragem Clinical Inc.

Not yet recruiting

CETIC-I (CEra Traction Improves Cervical Kyphosis -I)

Kyphosis | Cervical Kyphosis | Cervical Lordosis
Urigen

Completed

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

United States
Urigen

Completed

Study of U101 for Bladder Pain and/or Urgency

Pelvic Pain | Interstitial Cystitis | Bladder Diseases

United States
Stragen France

Completed

First-In-Human PainCart Study for STR-324

Pain

Netherlands
Urigen

Terminated

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
Toragen, Inc.

Recruiting

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

HPV Associated Cancers

United States
Qurgen Inc.

Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor

United States
miRagen Therapeutics, Inc.

Terminated

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Belgium
Curatek Pharmaceuticals, LLC

Completed

Multi-Center Study of New Medications to Treat Vaginal Infections (SMART GIVES)

Vaginal Infection

United States
miRagen Therapeutics, Inc.

Terminated

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Spain, Canada, United Kingdom, Australia, Italy, Belgium
miRagen Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

Keloid

United States
Curatek Pharmaceuticals, LLC

Completed

Multi-Center Study of New Medications to Treat Vaginal Infections (SMART GIVES)

Vaginal Infection

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

Healthy Volunteer

United States
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
AuriGen Medical Ltd

Recruiting

Zenith LAA Occlusion System

Stroke | Atrial Fibrillation | Left Atrial Appendage

New Zealand
Caregen Co. Ltd.

Not yet recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug

Healthy
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
Curatek Pharmaceuticals, LLC

Completed

Multi-Center Study of New Medications to Treat Vaginal Infections (SMART GIVES)

Vaginal Infection

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC (OPTIMA)

Carcinoma of Urinary Bladder, Superficial

Israel, Spain, Italy, Switzerland
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
UroGen Pharma Ltd.

Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Overactive Bladder

Israel
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Interstitial Cystitis | IC

Israel
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
CARsgen Therapeutics Co., Ltd.

Unknown

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

China
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria

Clinical Trials Sponsored by CuraGen Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations